LIWANLI Innovation Co., Ltd. (TPE:3054)
Taiwan · Delayed Price · Currency is TWD 30.85
-0.25 (-0.80%)
Feb 11, 2026, 1:30 PM CST
LIWANLI Innovation Revenue
LIWANLI Innovation had revenue of 51.45M TWD in the quarter ending September 30, 2025, with 118.61% growth. This brings the company's revenue in the last twelve months to 118.93M, up 23.96% year-over-year. In the year 2024, LIWANLI Innovation had annual revenue of 99.16M with 154.98% growth.
Revenue (ttm)
118.93M
Revenue Growth
+23.96%
P/S Ratio
20.92
Revenue / Employee
n/a
Employees
n/a
Market Cap
2.49B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 99.16M | 60.27M | 154.98% |
| Dec 31, 2023 | 38.89M | 4.90M | 14.41% |
| Dec 31, 2022 | 33.99M | -13.83M | -28.91% |
| Dec 31, 2021 | 47.81M | -229.07M | -82.73% |
| Dec 31, 2020 | 276.88M | 147.10M | 113.34% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Orient EuroPharma | 4.53B |
| Maywufa Company | 1.55B |
| TSH Biopharm Corporation | 1.27B |
| Allied Biotech | 821.81M |
| GeneFerm Biotechnology | 654.88M |
| Johnson Chemical Pharmaceutical Works | 567.06M |
| Tien Liang BioTech | 467.02M |
| PhytoHealth | 138.46M |